Cargando…

Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions

PURPOSE: Azacitidine and decitabine are hypomethylating agents (HMA), that is, both inhibit and deplete DNA methyltransferase 1 (DNMT1). HMAs are standard single-agent therapies for myelodysplastic syndromes and acute myelogenous leukemias. Several attempts to improve outcomes by combining HMAs with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zavras, Phaedon D., Shastri, Aditi, Goldfinger, Mendel, Verma, Amit K., Saunthararajah, Yogen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2021
Materias:	Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678301/ https://www.ncbi.nlm.nih.gov/pubmed/34551907 http://dx.doi.org/10.1158/1078-0432.CCR-21-2139

Ejemplares similares

P524: PHARMACODYNAMICALLY DEFINED METRONOMIC DOSING OF DECITABINE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA
por: Fedorov, Kateryna, et al.
Publicado: (2023)

Targeting sickle cell disease root-cause pathophysiology with small molecules
por: Saunthararajah, Yogen
Publicado: (2019)

Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen
por: Saleh, Mostafa F. M., et al.
Publicado: (2017)

Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiation
por: Saunthararajah, Yogen
Publicado: (2020)

Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort
por: Rabinovich, Emma, et al.
Publicado: (2021)

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
por: Jasra, Sakshi, et al.
Publicado: (2021)

Management of myelodysplastic syndromes after failure of response to hypomethylating agents
por: Gil-Perez, Angela, et al.
Publicado: (2019)

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors
por: Xu, Qing-Yu, et al.
Publicado: (2020)

5-aza-2′,2′-Difluroro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonucleotide Reductase Inhibitor for the Treatment of Cancer
por: Daifuku, Richard, et al.
Publicado: (2017)

PB1900: COMBINED TREATMENT WITH VENETOCLAX PLUS HYPOMETHYLATING AGENT OR CYTARABINE VERSUS TREATMENT WITH HYPOMETHYLATING AGENT ALONE IN ACUTE MYELOID LEUKEMIA IN POOR PROGNOSIS PATIENTS.
por: Saavedra, Minerva Montalvo, et al.
Publicado: (2023)

What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach
por: Awada, Hussein, et al.
Publicado: (2023)

Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells
por: Enane, Francis O., et al.
Publicado: (2018)

Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Zavras, Phaedon D., et al.
Publicado: (2023)

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

Combating breast cancer progression through combination therapy with hypomethylating agent and glucocorticoid
por: Chu, Yu-Hsin, et al.
Publicado: (2023)

Clinical Results of Hypomethylating Agents in AML Treatment
por: Cruijsen, Marjan, et al.
Publicado: (2014)

Increased incidence of thrombosis in a cohort of cancer patients with COVID-19
por: Zavras, Phaedon D., et al.
Publicado: (2021)

Opioid-Related Harms: Simplistic Solutions to the Crisis Ineffective and Cause Collateral Damage
por: Gallagher, Romayne
Publicado: (2018)

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
por: Urrutia, Samuel, et al.
Publicado: (2023)

Failures in reproductive health policy: overcoming the consequences and causes of inaction
por: Sher, Jonathan, et al.
Publicado: (2019)

Managing high-priced biologic agents: challenges and potential solutions
por: Li, Meng, et al.
Publicado: (2021)

Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia
por: Carraway, Hetty E., et al.
Publicado: (2020)

Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents
por: Johnson, Isla M., et al.
Publicado: (2022)

Fallacies of Using the Win Ratio in Cardiovascular Trials: Challenges and Solutions
por: Ajufo, Ezimamaka, et al.
Publicado: (2023)

High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects
por: Ebrahem, Quteba, et al.
Publicado: (2012)

The hypomethylating agent Decitabine causes a paradoxical increase in 5-hydroxymethylcytosine in human leukemia cells
por: Chowdhury, Basudev, et al.
Publicado: (2015)

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
por: Gangat, Naseema, et al.
Publicado: (2023)

Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter
por: Kordella, Chryssoula, et al.
Publicado: (2021)

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021)

Pandemic origins and a One Health approach to preparedness and prevention: Solutions based on SARS-CoV-2 and other RNA viruses
por: Keusch, Gerald T., et al.
Publicado: (2022)

Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML
por: Kubasch, Anne Sophie, et al.
Publicado: (2018)

Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia
por: Wu, Di, et al.
Publicado: (2021)

Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia
por: Báez-Gutiérrez, Nerea, et al.
Publicado: (2021)

Hypomethylation Causes MIR21 Overexpression in Tumors
por: Lu, Jun, et al.
Publicado: (2020)

Treatment of Low-Blast Count AML using Hypomethylating Agents
por: De Bellis, Eleonora, et al.
Publicado: (2017)

Differential Histone Posttranslational Modifications Induced by DNA Hypomethylating Agents
por: Malkaram, Sridhar A, et al.
Publicado: (2022)

The use of hypomethylating agents in hematologic malignancies: treatment preferences and results
por: Serin, Istemi, et al.
Publicado: (2021)

Opinion editorials: the science and art of combining evidence with opinion
por: Marchildon, Gregory P, et al.
Publicado: (2013)

Author Correction: Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia
por: Carraway, Hetty E., et al.
Publicado: (2020)

Management of Hodgkin Lymphoma in a Sickle Cell Patient: A Case Report
por: Ashraf, Farah, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_llsmccosgsv74o4ra2tajpn12v